Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data was written by Stahl, Stephen M.;Laredo, Sarah;Morrissette, Debbi Ann. And the article was included in Therapeutic Advances in Psychopharmacology in 2020.Recommanded Product: 839712-12-8 This article mentions the following:
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as ′atypical′ second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania/depression, cariprazine has now been approved for bipolar I depression. Addnl., post hoc analyses of bipolar I depressed subjects show that both those with and those without concurrent manic features were improved following treatment with cariprazine. Maintenance studies are in progress in bipolar disorder, as are studies to augment antidepressants in unipolar major depressive episodes insufficiently responsive to treatment. Here, we review specifically the efficacy and safety data of cariprazine in bipolar I disorder and discuss the hypothesized mechanism of action of cariprazine and how it could theor. be linked to caprazine′s broad therapeutic actions across the mood disorder spectrum. In the experiment, the researchers used many compounds, for example, 3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea (cas: 839712-12-8Recommanded Product: 839712-12-8).
3-(trans-4-(2-(4-(2,3-Dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea (cas: 839712-12-8) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Recommanded Product: 839712-12-8
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics